Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Events
    • Recent News
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Events
  • Recent News

Del Mar Pharmaceuticals Inc. (DMPI) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10

Jun 4, 2015

DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO

Jun 1, 2015

DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme

Jun 1, 2015

DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme

May 29, 2015

DelMar Pharmaceuticals Announces Upcoming Investor and Scientific Conference Presentations

May 27, 2015

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results and Provides Corporate Update

May 18, 2015

DelMar Pharmaceuticals to Present Additional Data on VAL-083 as a Potential Treatment for Temozolomide-Resistant GBM at AACR Advances in Brain Cancer Research Conference

May 7, 2015

DelMar Pharmaceuticals to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 30, 2015

DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM)

Apr 20, 2015

DelMar Pharmaceuticals Presents Updated Clinical Data on Phase I/II Study of VAL-083 in Refractory Glioblastoma Multiforme (GBM)

Apr 20, 2015
    • 1...
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • ...32
    © 2022 Kintara Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences